Monitor EHA 2026 presentations for ronde-cel safety and translational insights. Focus on PiNACLE trial data in H2 2026 and the Phase 3 PiNACLE-H2H trial for future valuation drivers.
Price Chart
Executive Summary
Lyell Immunopharma announced upcoming presentations of ronde-cel Phase 1/2 safety and translational data at the EHA 2026 Congress, but no clinical results were disclosed. The company's key catalysts remain the PiNACLE trial data expected in H2 2026 and a potential BLA submission in 2027. This is a routine pipeline update with no immediate impact.
Key Facts
- Ronde-cel safety and translational data to be presented at EHA 2026 (June 11-14).
- PiNACLE trial (3L+ LBCL) data expected H2 2026, pivotal data by mid-2027, BLA submission 2027.
- No new clinical data or financial guidance provided in this release.
Financial Impact
No financial impact from this filing; key catalysts are future data readouts.
Risk Factors
- Clinical data may not meet expectations; ronde-cel is still investigational.
- Competition from approved CAR-T therapies (Yescarta, Breyanzi).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307088 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | Insider Cluster | $15.49 $10.53 | ▼ −32.02% | ▼ −33.00% | $9.44 (−39.06%) |
Jul 22, 2026 10w ago | EFFECT | $12.84 $15.76 | ▲ +22.74% | ▲ +19.84% | $9.44 (−26.48%) |
Jun 15, 2026 15w ago | Insider Cluster | $12.44 $13.40 | ▲ +7.72% | ▲ +7.52% | $9.44 (−24.12%) |
Jun 12, 2026 16w ago | Press Release | $13.50 $15.01 | ▲ +11.19% | ▲ +9.41% | $9.44 (−30.07%) |
Jun 8, 2026 16w ago | Press Release | $12.31 $14.04 | ▲ +14.05% | ▲ +12.42% | $9.44 (−23.31%) |
Jun 4, 2026 17w ago | Press Release | $11.97 $14.04 | ▲ +17.29% | ▲ +15.43% | $9.44 (−21.14%) |
Apr 24, 2026 22w ago | DEFA14A | $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $9.44 (−58.27%) |
Apr 15, 2026 24w ago | EFFECT | $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $9.44 (−60.40%) |
Apr 3, 2026 25w ago | S-3 | $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $9.44 (−56.48%) |
Mar 12, 2026 29w ago | Press Release | $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $9.44 (−55.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access